Buy Medrol online without a doctor's prescription

medrol online
Medrol (Methylprednisolone) modifies the immune system response to various conditions and decreases inflammation
Active Ingredient: Methylprednisolone
Availability: In Stock (36 Packages)
Medrol 16mg
Product name Per Pill Savings (only today) Per Pack
30 pills $3.96 $118.85 ADD TO CART
60 pills $2.78 $70.86 $237.69 $166.83 ADD TO CART
90 pills $2.39 $141.72 $356.53 $214.811 ADD TO CART
120 pills $2.19 $212.58 $475.38 $262.80 ADD TO CART
180 pills $1.99 $354.31 $713.07 $358.76 ADD TO CART
270 pills $1.86 $566.89 $1069.61 $502.72 ADD TO CART
Medrol 4mg
Product name Per Pill Savings (only today) Per Pack
30 pills $1.15 $34.63 ADD TO CART
60 pills $0.90 $15.11 $69.25 $54.14 ADD TO CART
90 pills $0.82 $30.22 $103.88 $73.66 ADD TO CART
120 pills $0.78 $45.33 $138.51 $93.18 ADD TO CART
180 pills $0.73 $75.55 $207.76 $132.21 ADD TO CART
270 pills $0.71 $120.88 $311.65 $190.77 ADD TO CART
360 pills $0.69 $166.21 $415.53 $249.32 ADD TO CART

What is Medrol?

Medrol – glucocorticosteroid (GCS) for oral administration.

Methylprednisolone – the active substance of Medrol, is a glucocorticosteroid. It penetrates cell membranes and forms complexes with specific cytoplasmic receptors. Later, these complexes penetrate into the cell nucleus, where they bind to DNA (deoxyribonucleic acid, in particular, chromatin) and stimulate the transcription of mRNA (template ribonucleic acid) and the subsequent biosynthesis of various enzymes. This mechanism of action causes the effect of corticosteroids from systemic use.

Indications for use

  • Aspiration pneumonitis, symptomatic sarcoidosis, disseminated or fulminant pulmonary tuberculosis (as part of appropriate anti-tuberculosis chemotherapy), Leffler syndrome (in the absence of the effect of therapy with other drugs), berylliosis;
  • Combined therapy of tuberculous meningitis with a subarachnoid block or with the threat of a block;
  • Endocrine pathologies: congenital adrenal hyperplasia, primary and secondary adrenal insufficiency, subacute and chronic thyroiditis, hypercalcemia against the background of malignant neoplasms;
  • Idiopathic thrombocytopenic purpura and secondary thrombocytopenia (in adult patients), autoimmune hemolytic anemia, congenital hypoplastic anemia, erythrocytic anemia;
  • Treatment of acute forms of systemic connective tissue diseases in case of rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus, rheumatic polymyalgia, giant-cell arteritis (in some cases it is shown as maintenance therapy);
  • Skin pathologies: pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), herpetiform bullous dermatitis, fungoid mycosis, exfoliative dermatitis, severe seborrheic dermatitis, severe psoriasis;
  • Additional (short-term) therapy of diseases of the musculoskeletal system, including rheumatic diseases: with exacerbation or acute forms of the Comp.Accatec. osteoarthritis;
  • Treatment of severe (disabling) conditions (in case of failure of conventional therapy) in case of seasonal or perennial allergic rhinitis, drug hypersensitivity reactions, serum sickness, contact dermatitis, atopic dermatitis, bronchial asthma;
  • Chronic and severe acute inflammatory and allergic processes associated with eye diseases: keratitis, optic neuritis, chorioretinitis, iritis and iridocyclitis, allergic regional corneal ulcers, inflammation of the anterior segment of the eye, allergic conjunctivitis, sympathetic ophthalmia, diffuse posterior eyes, and inflammation of the anterior segment of the eye, and allergic conjunctivitis, sympathetic ophthalmia, diffuse posterior eye inflammation, and inflammatory posterior eye inflammation and allergic conjunctivitis, sympathetic ophthalmia, diffuse posterior eye inflammation
  • Palliative therapy for oncological diseases: in adults – leukemia and lymphoma, in children – acute leukemia;
  • Stimulation of diuresis and the achievement of remission of proteinuria in patients with nephrotic syndrome without uremia, against the background of systemic lupus erythematosus or idiopathic type;
  • Acute forms of ulcerative colitis and regional enteritis (for removing the patient from a critical condition);
  • Trichinosis with damage to the nervous system or myocardium;
  • Cerebral edema on the background of a brain tumor, exacerbation of multiple sclerosis;
  • As part of complex therapy for organ transplantation.


  • Breastfeeding period;
  • Hypersensitivity to the drug.

Precautions should be prescribed pills Medrol in patients with esophagitis, gastric ulcer and duodenal ulcers, gastritis, intestinal anastomosis (in the near history), latent or acute peptic ulcer, diverticulitis, ulcerative colitis (under the threat of perforation or abscess), hyperlipidemia, diabetes mellitus and predisposition to it, osteoporosis, myasthenia, hypothyroidism, acute psychosis, hyperthyroidism, subacute and acute myocardial infarction, arterial hypertension, congestive heart failure Residual, severe renal or hepatic function (especially with concurrent hypoalbuminemia) open-angle glaucoma; with herpes simplex (eye form), HIV infection (AIDS), measles, varicella, strongyloidosis.

For latent and active tuberculosis, severe forms of viral or bacterial infections, Medrol may be used only as part of specific therapy (it masks the symptoms of the disease and increases the risk of developing superinfection).

Not recommended for use in systemic fungal infections.

During pregnancy, the use of Medrol is permissible solely for absolute reasons.

Special instructions

Given the high risk of complications during glucocorticoid therapy, Medrol should be prescribed in the lowest doses that provide a clinical effect. In case of correction of the therapy regimen, the dose of the drug is reduced gradually.

The use of Medrol can potentiate the development of mental disorders, including insomnia, euphoria, depression, acute psychotic manifestations, or exacerbate the patient’s emotional instability. Prone to psychotic reactions in patients during or after stress is shown to increase the dose of the drug.

In the period of Medrol intake in a dose that produces an immunosuppressive effect, the patient should not be given live or live attenuated vaccines, administration of killed or inactivated vaccines is indicated, and the response to their administration can be reduced. If the dose does not have an immunosuppressive effect, immunization can be carried out according to the appropriate indications.

Action Medrol can erase the clinical picture of some infections or cause the development of new ones. During the period of taking the drug, the body may lose resistance to infections or the ability to localize the infectious process.

The risk of developing infectious complications increases in proportion to the increase in the dose of Medrol, both in monotherapy and in combination with other immunosuppressants. Infections caused by pathogenic microorganisms (viruses, fungi, bacteria, worms or protozoa) can occur in a mild and severe form, even death.

With active tuberculosis, use is indicated for the treatment of disseminated and fulminant tuberculosis, in combination with appropriate anti-tuberculosis chemotherapy. When prescribing to patients with positive tuberculin tests or latent tuberculosis, the process can be reactivated, so the treatment should be accompanied by strict medical supervision. Long-term use of methylprednisolone in such patients should be carried out with the simultaneous appointment of appropriate prophylactic treatment.

Caution should be used in the treatment of herpes simplex eyes because of the risk of perforation of the cornea.

Long-term therapy can contribute to the accession of a secondary ocular viral or fungal infection, cause the development of allergic reactions, the occurrence of posterior subcapsular cataracts, glaucoma with possible damage to the optic nerve.

High doses of methylprednisolone can cause high blood pressure, potassium excretion, and sodium and water retention. During the period of treatment, the patient should limit the intake of table salt and prescribe the administration of potassium preparations.

Medrol increases calcium excretion.

A frequent side effect of prolonged use of high doses of the drug is osteoporosis.

A long-term daily dosing regimen with Medrol intake several times a day in the treatment of children should be used only if absolutely necessary, since it can cause a delay in the growth of the child. Alternating therapy allows you to minimize or avoid this undesirable effect.

A gradual reduction in the dose of the drug allows to minimize the manifestations of secondary insufficiency of the adrenal cortex. This type of pathology can be observed after the end of treatment for a few more months, so if you experience any stressful situations in the specified period, it is necessary to re-appoint Medrol. In connection with a possible violation of the secretion of mineralocorticoids, the concomitant use of mineralocorticoids and / or electrolytes is shown.

A more pronounced effect of glucocorticosteroids is observed in patients with cirrhosis and hypothyroidism.

Therapy can mask signs of peptic ulcers, so without severe pain the patient may experience bleeding or perforation.

On the background of therapy, there have been cases of development in patients with Kaposi’s sarcoma, with the cancellation of Medrol, the onset of clinical remission is possible.

Negative effects on reproductive function, mutagenic and carcinogenic effects of the drug have not been established.

Impact on the ability to drive motor vehicles and complex mechanisms

Since during the treatment with Medrol, the development of dizziness, weakness and visual impairment is possible, it is recommended that persons who drive vehicles, as well as engaged in activities that require a quick psychomotor reaction and high concentration of attention, use caution.

Use during pregnancy and lactation

  • pregnancy: the use of Medrol is possible only by absolute indications;
  • lactation period: therapy is contraindicated.

Relevant studies of the effect of GCS on human reproductive function have not been conducted. If necessary, the use of Medrol in women of childbearing age or during pregnancy requires an assessment of the possible positive effect in comparison with the potential risk to the embryo, fetus or mother.

How to use?

Medrol tablets are taken orally.

The dosage regimen is prescribed by the doctor on the basis of clinical indications.

Selection of the dose must be made individually, taking into account the patient’s response to therapy.

Recommended daily dosing:

  • Adults: the initial dose is 4-48 mg, then the correction is made depending on the nature of the disease and the patient’s condition. So with multiple sclerosis, the dose can be 200 mg, brain edema – 200-1000 mg, organ transplants – at the rate of up to 7 mg per 1 kg of body weight per day. In the absence of a therapeutic effect as a result of a sufficient Medrol intake period, the drug should be replaced by another agent;
  • Children: the dose is determined based on the surface area or weight of the child, so for the treatment of adrenal insufficiency, the dose can be 3.33 mg per 1 m2 or 0.18 mg per 1 kg per day, for other indications – 12.5-50 mg per 1 m2 or 0.42-1.67 mg per 1 kg per day. The daily dose is evenly distributed in 3 doses.

Side effects

  • Digestive system: gastric bleeding, peptic ulcer (with the risk of perforation and bleeding), pancreatitis, intestinal perforation, esophagitis, increased activity of alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase in the serum (usually the changes are transitory and insignificant);
  • Metabolism: chronic heart failure in predisposed patients, sodium retention, increased blood pressure, loss of potassium, hypokalemic alkalosis, fluid retention in the body, negative nitrogen balance against the background of protein catabolism;
  • Endocrine system: the development of Cushing’s syndrome, hirsutism, suppression of the pituitary-adrenal system, reduced tolerance to carbohydrates, the emergence of latent diabetes, in patients with diabetes, increased demand for oral hypoglycemic agents or insulin, menstrual disorders; in children – growth retardation;
  • Musculoskeletal system: muscle weakness, steroid myopathy, osteoporosis, tendon ruptures (most commonly Achilles tendon), vertebral compression fractures, pathological fractures, aseptic necrosis of the epiphysis of tubular bones;
  • Nervous system: increased intracranial pressure, mental disorders, brain pseudo-tumor, seizures;
  • Organ vision: increased intraocular pressure with the risk of damage to the optic nerve, posterior subcapsular cataract, exophthalmos;
  • Allergic reactions: hypersensitivity reactions, including allergic systemic reactions, possibly suppressing reactions in skin tests;
  • Dermatological reactions: petechiae and ecchymosis, slowing the healing process of wounds, reducing strength and thinning of the skin;
  • Other: activation of latent infections, distortion of the clinical picture in infectious pathologies, the occurrence of opportunistic infections, GCS withdrawal syndrome.


The clinical symptoms of acute overdose are not described. There is practically no information about cases of acute toxicity in case of overdose of GCS.

The main symptoms (with frequent re-admission – daily or several times a week, over a long period): Cushing’s syndrome and other complications characteristic of prolonged treatment of GCS.

Therapy: symptomatic.

There is no specific antidote. Methylprednisolone is derived from dialysis.

Save your money
Mega Discounts on Big Packs